M. WilliamAudehMDMS

Oncology • Sherman Oaks, CA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Chief Medical Officer, Agendia Inc.

Join to view full profile

Dr. Audeh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Audeh's full profile

Already have an account?

Office
14816 OTSEGO ST
Sherman Oaks, CA 91403
Phone+1 310-849-0561
Is this information wrong?

Summary

Chief Medical Officer, Agendia, Inc.
Breast Cancer Genomics

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1986 - 1989
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1982 - 1986
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 1983 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Join now to see all

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Start of enrollment: 2014 Feb 25
Terminated
Phase 3
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Start of enrollment: 2014 Nov 20
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

16 citations
A breast cancer gene signature for indolent disease.
Leonie J. M. J. Delahaye, CA Drukker, Christa Dreezen, Anke T. Witteveen, Bob Chan, Mireille Snel, Ines J. Beumer, René Bernards, M. William Audeh, Laura J. van't Veer...> ;Breast Cancer Research and Treatment. 2017 Apr 27
122 citations
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Ursula A. Matulonis, Richard T. Penson, Susan M. Domchek, Bella Kaufman, Ronnie Shapira-Frommer, M. W. Audeh, Stan B. Kaye, L. R. Molife, Karen A. Gelmon, Jane Roberts...> ;Annals of Oncology. 2016 Jun 1
215 citations
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried...> ;Gynecologic Oncology. 2016 Feb 1
14 citations
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology
Yu Xie, William J. Collins, M. William Audeh, Stephen L. Shiao, Roberta A. Gottlieb, Marc T. Goodman, C. Noel Bairey Merz, Puja K. Mehta> ;Current Treatment Options in Cardiovascular Medicine. 2015 Oct 21
1241 citations
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M. Stemmer,...> ;Journal of Clinical Oncology. 2015 Jan 20
32 citations
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
M. William Audeh> ;Pharmacogenomics and Personalized Medicine. 2014 Oct 3
29 citations
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
David M. Hyams, Arlene Chan, Celia de Oliveira, Raymond Snyder, Jeferson Vinholes, M. William Audeh, Victor M. Alencar, Janine Lombard, Bijoyesh Mookerjee, John Xu, Ka...> ;Investigational New Drugs. 2013 Jun 26
19 citations
Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer
Susan M. Domchek, Gillian Mitchell, Geoffrey J. Lindeman, Nadine Tung, Judith Balmaña, Steven J. Isakoff, Rita K. Schmutzler, M. William Audeh, Niklas Loman, Clare L. ...> ;Journal of Clinical Oncology. 2011 Nov 10
920 citations
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas L...> ;Lancet. 2010 Jul 24
1417 citations
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
Andrew Tutt, Mark E. Robson, Judy Garber, Susan M. Domchek, M. W. Audeh, J. N. Weitzel, Michael Friedlander, B. K. Arun, Niklas Loman, Rita K. Schmutzler, Andrew M War...> ;Lancet. 2010 Jan 1
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.
Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J> ;J. Clin. Oncol.. 2009-06-20
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.
Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J> ;J. Clin. Oncol.. 2009-05-20
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer.
Audeh MW, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Carmichael J, Tutt A> ;J. Clin. Oncol.. 2009-05-20
1 citations
MDS and secondary AML: an evolutionary perspective.
M. William Audeh> ;Cancer Treatment and Research. 2001 Jan 1
25 citations
Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma.
John G. Strickler, M. William Audeh, Cedith M. Copenhaver, Roger A. Warnke> ;Cancer. 1988 May 1
Join now to see all